Pharvaris said its deucrictibant achieved a Phase 3 win in a second study, reinforcing the case for its hereditary angioedema therapy as the Swiss biotech awaits an FDA decision. The latest outcome strengthens the benefit narrative for a condition where options remain limited and long-term prophylaxis decisions depend on both efficacy and safety. The company framed the Phase 3 improvement as building momentum for regulatory evaluation, with the next inflection point being the timing and scope of the FDA verdict. For clinicians and developers, an additional positive Phase 3 study typically shifts discussions toward label design, positioning, and potential payer adoption. The readout also positions Pharvaris for follow-on planning around regulatory filings and potential commercialization pathways in the HAE space.